Business
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. Guggenheim's Emerging Outlook: Biotech SummitFormat: Fireside ChatDate: Thursday, February 12, 2026Time: 3:00 – 3:25 p.m. ET Oppenheimer 36th Annual Healthcare Life Sciences Conference Format
About this update from Climb Bio, Inc.
WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. Guggenheim's Emerging Outlook: Biotech Summit Format: Fireside Chat Date: Thursday, February 12, 2026 Time: 3:00 – 3:25 p.m. ET Oppenheimer 36 th Annual Healthcare Life Sciences Conference Format: Fireside Chat Date: Wednesday, February 25, 2026 Time: 1:20 – 1:50 p.m. ET Leerink Global Healthcare Conference Format: Fireside Chat Date: Monday, March 9, 2026 Time: 2:20 – 2:50 p.m. ET The live webcasts will be accessible via the “Investors & Media” section of the Climb Bio website . Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days. About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy. For more information, please visit climbbio.com . Investors and Media Carlo Tanzi, Ph.D. Kendall Investor Relations [email protected]